Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$34M
- −39.2% YoY
- EPS (diluted)
- −$0.59
- −11.3% YoY
Source: XBRL data from the CAPRICOR THERAPEUTICS, INC. (CAPR) Q1 2026 10-Q on SEC EDGAR. USD.
CAPRICOR THERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial product sales
- Net loss $33.9M vs $24.4M YoY; no margin percentage disclosed
- Deramiocel R&D $13.0M, up 69%; exosome research $0.8M, down 47%
- Cash, equivalents and securities $278.6M vs $318.1M at December 31, 2025
- Operating cash use $29.3M vs $6.4M YoY; 2026 Deramiocel spending forecast $100M-$125M
Risk Factors
- Newly added litigation risk: NS lawsuit alleges inadequate Deramiocel launch preparation and seeks rescission of the January 25, 2022 U.S. Distribution Agreement
- Most material update: Direct commercialization strategy now depends on litigation outcome and potential replacement of NS as U.S. distributor
- Regulatory/compliance risk: No product candidates have FDA approval, creating uncertainty around Deramiocel commercialization
- Operational risk: No experience commercializing pharmaceutical products at commercial scale
- Financial risk: Continued substantial net losses and need for additional capital to fund trials and development programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CAPRICOR THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.